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The tumor necrosis factor (TNF) superfamily member a
proliferation-inducing ligand (APRIL) has been shown
to play an important role in B-cell biology (1, 2). In vitro,
APRIL drives both proliferation and survival of human
and murine B cells (1), while in vivo, it induces in mice a
spleen enlargement because of inﬁltration by CD5-posi-
tive B lymphocytes (3). APRIL expression has been
reported, under physiological conditions, in several
hematopoietic cells (neutrophils, monocytes, macrophag-
es, dendritic cells, B and T lymphocytes and osteoclasts)
(2). It has also been detected in solid tumors and in
B-cell-derived malignancies (2). Initially produced as a
homotrimeric type-II transmembrane protein, APRIL is
mainly released in the extracellular compartment as a
soluble form (4). It interacts with two canonical recep-
tors, the B-cell maturation antigen (BCMA) and the
transmembrane activator, calcium modulator, and cyclo-
philin ligand interactor (TACI) (2). Furthermore, it has
been shown to react also with the heparan sulfate side
chain of proteoglycans (HSPG), which is supposed to
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facilitate TACI and ⁄or BCMA signaling (5). Several
studies have reported the involvement of APRIL in neo-
plastic diseases (6), especially in B-cell-derived malignan-
cies (2). In vitro studies have demonstrated that APRIL
induces the proliferation of human follicular lymphoma
B cells (7), promotes the survival of diffuse large B-cell
lymphoma cells (8), the survival and proliferation of
Hodgkin’s lymphoma cell lines (9) and, ﬁnally, protects
from apoptosis dexamethasone-treated human multiple
myeloma cells (10). Additional studies have indirectly
indicated a role of APRIL in the pathogenesis of high-
grade non-Hodgkin’s (11) and Hodgkin’s lymphomas
(12). Increasing lines of evidence are showing that
APRIL is also involved in the pathogenesis of B-cell
chronic lymphocytic leukemia (B-CLL), which is charac-
terized by the progressive accumulation of mature and
apoptosis-resistant CD5-positive B lymphocytes in lym-
phoid tissues, bone marrow (BM) and peripheral blood.
Recent reports have demonstrated that the majority of
B-CLL cells express detectable levels of BCMA and TACI
on their surface (13, 14) and that malignant lymphocytes
themselves may express and release APRIL (15). Other
reports have indicated in nurse-like cells differentiating
from CD14-positive cells the main source of APRIL in
B-CLL (16). In vitro, treatment of B-CLL cells with
recombinant human APRIL (rhAPRIL) has been shown
to promote B-CLL cells survival through the activation of
the NF-kB pathway (13). Interestingly, approximately
40% of aged human APRIL transgenic mice develop a
B1-cell-associated neoplasia resembling B-CLL (2).
On the basis of these experimental data, we aimed to
establish the impact of APRIL serum (sAPRIL) levels on
the clinical outcome of patients with B-CLL, assessed by
Cox’s proportional hazard modeling in both the univari-
ate and multivariate analyses. To pursue this aim, we
retrospectively evaluated 130 patients observed in our
Institution, studying the correlation between sAPRIL
levels and the time elapsing from the diagnosis to the
ﬁrst treatment (TTFT). According to our study,
increased levels of sAPRIL appeared predictive of a
shorter TTFT independently from other prognostic fac-
tors such as high lymphocyte count, high b2M, advanced
clinical stage and ZAP-70 expression. This also applied
when a subgroup of low b2M, early-stage, ZAP-70-nega-
tive patients were separately evaluated, further conﬁrm-
ing the potential clinical value of sAPRIL measurement
in B-CLL.
Patients and methods
Patients
We retrospectively evaluated 130 patients diagnosed
with B-CLL between November 1993 and March 2009
and followed from then on at our Institution. Diagnosis
was based or reviewed according to the most recent
published criteria (17, 18), and the patients were selected
only on the basis of availability of sera collected at
diagnosis and immediately frozen. This series encom-
passes 35% of the whole B-CLL population diagnosed
by our Institution in the aforementioned period.
Informed consent was obtained according to the legal
regulation present in Italy at the time of diagnosis, and,
in the case of recent samples, it was provided according
to the Declaration of Helsinki for the collection and use
of biological samples for Institutional Review Board
(IRB)-approved research purposes. Patient’s evaluation
included history, physical examination, laboratory evalu-
ation (complete blood count and chemistries), peripheral
blood smear morphology and BM aspirate and biopsy.
Clinical stage was measured according to Binet scale.
On the basis of the equation devised by Delgado and
coll (19), b2M levels, available in 108 patients (83%),
were adjusted according to patient’s individual glomeru-
lar ﬁltration rate (GFR): GFR-b2M = b2M (mg ⁄L) ·
GFR (mL ⁄min) ⁄ 100. Cutoff level was established at
2 mg ⁄L (19). CD38 expression was evaluated in periph-
eral blood from 105 patients (81%) by ﬂow-cytometry
(cutoff: 30% of B lymphocytes). ZAP-70 expression was
evaluated in BM specimens from 116 patients (89%) by
immunohistochemistry (IHC). The reliability of this
technique and its correlation with immunoglobulin
heavy chain (IgVH) gene mutational status has already
been described in the literature (20, 21). Therefore, con-
sidering that IgVH mutational status was available only
in the most recent cases of our series (43%) and that in
our study we observed an 88% concordance rate
between IgVH mutational status and ZAP-70 expres-
sion, we decided to use ZAP-70 as surrogate for statisti-
cal analysis. Data regarding FISH analysis, available
only in a minority of patients (32%), were excluded
from statistical analysis owing to the methodological
reasons. Clinical and biological data of the entire series
are summarized in Table 1.
APRIL measurement
sAPRIL levels were measured by ELISA (Bender Med-
System GmbH, Vienna, Austria), according to the Man-
ufacturer’s instructions in serum samples collected and
frozen at diagnosis. No systematic bias has been intro-
duced in deciding which sera to stock at diagnosis, nor
in the freezing procedure. All the ELISAs have then been
run between the end of 2009 and the beginning of 2010.
Measurements were taken in triplets, and mean values
were taken as ﬁnal data. The calculated median intra-
assay variability was 7.57% (range: 5.22–9.04), while
inter-assay variability coefﬁcient of variation was 9.2%.
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Statistical analysis
sAPRIL appeared as a log-normal variable in samples
from healthy donors. As such, its natural logarithm fol-
lowed a normal frequency distribution when tested by
means of a Shapiro–Wilk test (P = 0.464), with gaussian
symmetry around the median. Based on these results, we
applied a logarithmic conversion to all sAPRIL data,
and then, we used the median ln(sAPRIL) (=1.7851) as
cutoff for signiﬁcance to divide our series into two
groups of statistically comparable size (APRILLOW,
n = 72 and APRILHIGH, N = 58). These two groups
were then compared according to their characteristics
using Fisher’s exact test and Pearson’s chi-squared, for
proportions, and independent Student’s t-test, for para-
metric variables. Considering that the two groups were
balanced for all clinical and biological parameters, we
used the same cutoff – median ln(sAPRIL) – to assess
the potential prognostic power of sAPRIL levels and for
further statistical evaluation.
sAPRIL levels were then correlated with other numeric
variables (age, hemoglobin, lymphocyte and platelet
counts, GFR-b2M) by means of a linear regression [ordin-
ary least squares method (OLS)], and the correlation of
sAPRIL with categorical and binary variables was tested
by means of the Mann–Whitney U test (between two
groups) and the Kruskall–Wallis test (among multiple
groups). ZAP-70 and CD38 expression by B-CLL cells
were considered as binary variables, and correlation with
sAPRIL levels was tested by the Mann–Whitney U test.
Overall survival (OS) was deﬁned as the time from diagno-
sis to death from all causes or to last follow-up, TTFT
was deﬁned as the time from diagnosis to any initial treat-
ment or, alternatively, as time from diagnosis to last fol-
low-up. Survival data were considered as per March 2010,
when 80 patients were alive (61.5%) with a median follow-
up of 88 months (range 12–195). Progression and indica-
tion to treatment were deﬁned according to the National
Cancer Institute-sponsored working group guidelines for
chronic lymphocytic leukemia (17, 18). Brieﬂy, criteria for
initiating primary treatment were the following: (i) the
presence of constitutional symptoms; (ii) evidence of pro-
gressive marrow failure as manifested by the development
of, or worsening of, anemia and ⁄or thrombocythemia; (iii)
autoimmune anemia and ⁄or thrombocytopenia poorly
responsive to corticosteroid therapy; (iv) massive (>6 cm
below the left costal margin) or progressive splenomegaly;
(v) massive nodes or clusters (>10 cm in longest diameter)
or progressive lymphadenopathy; (vi) progressive lympho-
cytosis with an increase of >50% over a 2-month period
or an anticipated doubling time of <6 months (17, 18). In
any case, absolute lymphocyte count was never used as the
sole indicator for the treatment. Our Institution did not
change the policy on indications to treatment over the
years encompassed in the study.
OS and TTFT curves were plotted according to Kap-
lan–Meier’s method, and differences between the groups
were tested using the log-rank test (P value for signiﬁ-
cance = 0.05). The evaluation of putative risk factors was
made using Cox’s proportional hazard modeling to obtain
hazard ratios (HR) and their 95% conﬁdence intervals
(95% CI), in both univariate and multivariate modes. All
statistical calculations were carried out using Stata IC
v.10.0 (StataCorp, College Station, TX, USA) for Micro-
soft Windows.
Results
APRIL is significantly increased in patients with B-CLL
sAPRIL serum levels were signiﬁcantly increased in
patients with B-CLL as compared with those of age- and
gender-matched healthy donors (mean ± SD, 14.61 ng ⁄
mL ± 32.65, n = 130 vs. 4.19 ± 3.42 ng ⁄mL, n = 25,
respectively: P < 0.001; Fig. 1). In patients with B-CLL,
Table 1 Patients clinical–biological characteristics and distribution according to median ln(sAPRIL) levels
OVERALL APRILLOW GROUP APRILHIGH GROUP P
Number of patients 130 72 58
Median age, years (range) 64 (33–92) 62 (34–92) 66.5 (33–88) NS
Male ⁄ Female gender 79 ⁄ 51 42 ⁄ 30 37 ⁄ 21 NS
Binet stage (A vs. B–C) 90 ⁄ 40 50 ⁄ 22 40 ⁄ 18 NS
Mean hemoglobin (g ⁄ dL) ±SD 13.5 ± 1.98 13.7 ± 1.53 13.3 ± 2.42 NS
Mean lymphocyte count (·109 ⁄ L) ±SD 26.63 ± 33.70 21.16 ± 26.70 29.02 ± 40.72 NS
Mean platelet count (·109 ⁄ L) ±SD 209.600 ± 103.9 198.167 ± 67.2 223.793 ± 135.9 NS
GFR-b2M1 (mg ⁄ L) ±SD 2.27 ± 1.68 2.35 ± 2.02 2.17 ± 1.12 NS
CD38-positive cases2 61 ⁄ 105 (58.1%) 37 ⁄ 57 (64.9%) 24 ⁄ 48 (50.0%) NS
ZAP-70-positive cases3 76 ⁄ 116 (65.5%) 41 ⁄ 63 (65.0%) 35 ⁄ 53 (66.0%) NS
IgVH gene mutational status
4
Unmutated 40 (67.8%) 24 ⁄ 40 (60.0%) 16 ⁄ 40 (40.0%) NS
Mutated 19 (32.2%) 12 ⁄ 19 (63%) 7 ⁄ 19 (37.0%) NS
Missing: 22 patients1, 25 patients2, 14 patients3, 74 patients4.
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sAPRIL did not appear to correlate with any of the fol-
lowing clinical–biological parameters: age, gender, clini-
cal stage, hemoglobin levels, lymphocyte or platelet
count, GFR-b2M, CD38 or ZAP70 (data available from
the authors).
APRIL identifies patients at high risk of earlier
progression
As described earlier, median ln(sAPRIL) (1.7851) was
used as cutoff allowing to identify two groups of patients
APRILLOW (n = 72) and APRILHIGH (n = 58), who
were comparable regarding all clinical–biological param-
eters (Table 1). Pearson’s chi-squared and Fisher’s exact
test showed no signiﬁcant association between APRIL
risk group and stage or ZAP-70 expression when all
patients were considered. Furthermore, sAPRIL levels
did not signiﬁcantly differ between ZAP-70-positive and
ZAP-70-negative patients in subgroups deﬁned by clinical
stage (A vs. B–C). Interestingly, when considering TTFT,
the two groups of patients revealed a different outcome
(Fig. 2). Indeed, median TTFT was 34 months in the
APRILLOW group and 17 months in the APRILHIGH
(P = 0.035). OS, on the contrary, was not signiﬁcantly
different in the two groups (median OS 122 vs.
144 months, P = NS).
APRIL is a predictor of shorter TTFT, independently
from favorable prognostic factors
We evaluated prognostic value of age, gender, lymphocyte
count at diagnosis, clinical stage, GFR-b2M > 2 mg ⁄L,
ZAP-70 and CD38 expression and median ln(sAPRIL), at
both the univariate and multivariate levels. At the univari-
ate analysis, a lymphocyte count at diagnosis
>30 · 109 ⁄L, GFR-b2M > 2 mg ⁄L, clinical stage B–C,
ZAP-70 expression and ln(sAPRIL) above the median
were signiﬁcantly associated with earlier progression:
GFR-b2M > 2 mg ⁄L, stages B–C, ZAP-70 expression
and ln(sAPRIL) above the median remained indepen-
dently predictive also at a subsequent multivariate analysis
(Table 2).
When we stratiﬁed our series according to stage, we
found that ln(sAPRIL) above the median was able to
predict earlier TTFT in patients in stage A (n = 90),
with a median TTFT of 45 months in the APRILLOW
(n = 50) and 32 months in the APRILHIGH (n = 40)
group, respectively (P = 0.019). On the contrary,
ln(sAPRIL) prognostic value was lost in advanced (B–C)
stages (n = 40; P = NS). Signiﬁcantly, ln(sAPRIL) was
also a powerful predictor of earlier TTFT in ZAP-70-
negative patients (n = 40), with a median TTFT of
53 months in APRILLOW (n = 22) and 31 months in
APRILHIGH (n = 18) patients, respectively (P = 0.025).
ln(sAPRIL) prognostic value was lost in the case of
ZAP-70-positive patients (n = 76) (P = NS). Interest-
ingly, in a relatively small group of patients (n = 20)
characterized by all the independent favorable prognostic
factors resulting from our multivariate analysis (GFR-
b2M < 2mg ⁄L, stage A, lack of ZAP-70 expression),
ln(sAPRIL) above the median was still able to discrimi-
nate a subgroup of patients with a signiﬁcant lower
TTFT (P = 0.026; Fig. 2).
Figure 1 sAPRIL levels (ng ⁄mL, mean ± standard deviation) in
healthy donors (n = 25) and in patients with B-chronic lymphocytic
leukemia (n = 130).
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Figure 2 Time to the first treatment according to ln(sAPRIL) levels in
the overall population and in a subgroup of patients (insect) character-
ized by favorable prognostic factors (b2M < 2 mg ⁄ L, stage A, lack of
ZAP-70 expression).
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Discussion
The clinical course of patients with B-CLL is highly vari-
able, with life expectancies ranging from months to sev-
eral years. During the last decades, many efforts have
been made to identify prognostic markers capable of dis-
criminating high-risk patients who might beneﬁt from
more aggressive approaches. Nowadays, several validated
prognostic markers are available (22), and the more
recent efforts are aimed at identifying novel factors use-
ful for reﬁning the prognosis of risk categories identiﬁed
by already existing markers. The involvement of sAPRIL
in the pathogenesis of lymphoproliferative diseases
prompted us to explore its prognostic role in the whole
series of patients with B-CLL and particularly in well-
deﬁned risk categories. Previously, Planelles et al. (23)
have demonstrated that among 95 patients affected by
B-CLL, those with serum concentration of APRIL above
median had signiﬁcantly poorer OS. In that study,
though, APRILhigh group consisted mostly of patients
with clinical unfavorable features, such as Binet B–C. In
the other study available on this topic, Bojarska-Junal
et al. (24) have analyzed APRIL plasma levels with
regard to OS in a cohort of 183 patients with B-CLL,
demonstrating that APRIL plasma levels above median
correlated with more advanced (Rai 3–4) stages and pre-
dicted worse OS. The fact that also in this case, patients
with high APRIL concentrations clustered in unfavorable
or advanced stage groups may have partially accounted
for their poorer OS. Differently from the two previous
reports, we did not observe a predictive role of sAPRIL
in OS, but in TTFT. In our opinion, this ﬁnding may be
due to the fact that in our series, APRIL divided patients
into two groups characterized by statistically comparable
adverse clinical and biological features. Moreover, heter-
ogeneous treatments adopted throughout the two dec-
ades covered by our study could also have impacted on
the ﬁnal outcome of patients (25). Unfortunately, no
data on TTFT are available for comparison from the
aforementioned studies (23, 24).
However, in the present report, we demonstrate that
increased sAPRIL levels can independently predict a
shorter TTFT and identify a subgroup of poor-risk
patients otherwise characterized by independent favor-
able predictors (GFR-b2M < 2 mg ⁄L, stage A, lack of
ZAP-70 expression), according to the multivariate analy-
sis of our series. Interestingly, the inverse correlation
between increased sAPRIL levels and the time elapsing
from the diagnosis to the ﬁrst treatment, particularly in
low-risk patients, suggests a role for sAPRIL in support-
ing the resistance to apoptosis of malignant B lympho-
cytes, independently of favorable intrinsic features.
Furthermore, as we did not ﬁnd any association between
sAPRIL levels and number or biological characteristics
of malignant B-lymphocytes, it is conceivable to hypoth-
esize a release of sAPRIL from the microenvironment.
As a matter of fact, an increasing number of studies are
indicating a role of the microenvironment in promoting
and stimulating the proliferation and survival of B-CLL
lymphocytes through the release of soluble mediators
(26). We are aware that, given the relatively small sample
size and the retrospective nature of the study our obser-
vation should be prospectively validated in a larger
cohort of patients with B-CLL, fully characterized
according to the most signiﬁcant prognostic factors
including cytogenetics.
We believe that besides the speculative interest, our
ﬁndings add relevance to sAPRIL as a prognostic indica-
tor and possible therapeutic target, especially considering
the availability of agents capable of interfering with
APRIL and currently tested in the clinical setting (27,
28).
Acknowledgements
This study has been supported by grants from Regione
Veneto ‘Ricerca Sanitaria Finalizzata’; Associazione
Italiana Ricerca sul Cancro (AIRC) and Fondazione
CARIVERONA.
Conflict of interest
The authors declare no competing ﬁnancial interests.
Table 2 Factors predictive of earlier time to the first treatment according to Cox’s proportional hazard modeling
Unadjusted HR (95% CI) P Adjusted HR (95% CI) P
Age >65 yrs 1.29 (0.89–1.85) NS
Male gender 1.14 (0.79–1.65) NS
Lymphocyte count >30 · 109 ⁄ L 2.06 (1.31–3.22) 0.002 1.38 (0.80–2.36) NS
Binet stage B–C 6.02 (3.71–9.77) <0.001 4.38 (2.35–8.14) <0.001
GFR-b2M ‡ 2mg ⁄ L 1.86 (1.25–2.76) 0.002 1.65 (1.02–2.66) 0.042
ZAP-70 expression 2.03 (1.30–3.17) 0.002 1.72 (1.01–2.92) 0.046
CD38 expression 1.49 (0.98–2.27) NS
sAPRIL ‡ median ln 1.48 (1.03–2.14) 0.036 1.81 (1.16–2.84) 0.010
GFR, glomerular filtration rate; HR, hazard ratios.
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